Ocugen Inc
OCGN
查看详细走势图
1.330USD
0.0000.00%
收盘 02/06, 16:00（美东）报价延迟15分钟
415.39M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
-8.28%
1月
-16.35%
6月
+33.00%
今年开始到现在
-1.48%
1年
+86.69%
查看详细走势图
TradingKey Ocugen Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Ocugen Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名133/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.00。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Ocugen Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Ocugen Inc亮点
亮点风险
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
业绩高增长
公司营业收入稳步增长，连续3年增长62.98%
业绩增长期
公司处于发展阶段，最新年度总收入4.05M美元
估值低估
公司最新PE估值-6.13，处于3年历史低位
机构加仓
最新机构持股72.72M股，环比增加10.84%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值45.06K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.60
分析师目标
根据
5
位分析师
买入
评级
9.000
目标均价
+538.30%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Ocugen Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Ocugen Inc简介
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
公司代码OCGN
公司Ocugen Inc
CEOMusunuri (Shankar)
网址https://ocugen.com/
相关品种
